title: [Efficacy and safety of levofloxacin to non-gonorrheal urethritis].
abstract: We investigated the efficacy and safety of levofloxacin (LVFX) 500mg once a day in patients with non-gonorrheal urethritis. Men, aged 20 years or older, with urethritis symptoms, and detection of Chlamydia trachomatis (C. trachomatis) or Mycoplasma genitalium (M. genitalium) by a microbiological examination were eligible for this study. Patients were administered LVFX 500mg, orally, once a day and the dosage period was seven days. We assumed 22 patients for a safety and efficacy analysis. In 22 patients, 17 patients had urethritis with C. trachomatis, 4 patients urethritis with M. genitalium, and one patient mixed infection of C. trachomatis and M. genitalium. In the clinial study, the primary endpoint was set as the bacteriological eradication rate at two to four weeks after completion of treatment. The bacterial eradication rate in the urethritis was 86.4% (19/22). The bacterial eradication rate in the urethritis with C. trachomatis, M. genitalium, and mixed infection of C. trachomatis and M. genitalium were 94.1% (16/17), 50.0% (2/4), 100% (1/1), respectively. A significant difference was not recognized among the three groups. The clinical efficacy at two to four weeks after completion of treatment was 90.9% (20/22). The clinical efficacy rates in the urethritis with C. trachomatis, M. genitalium, and mixed infection of C. trachomatis and M. genitalium were 100% (17/17), 50.0% (2/4), 100% (1/1), respectively. The efficacy rate of urethritis with M. genitalium was significantly low. No adverse drug reactions were observed. These results suggest that once-a-day levofloxacin (500mg) is effective and safe treatment for non-gonorrheal urethritis.
authors.affiliation: Fuji City General Hospital.
authors.forename: Shoichi
authors.initials: S
authors.lastname: Onodera
authors.forename: Yasuhiko
authors.initials: Y
authors.lastname: Onoe
authors.forename: Takahide
authors.initials: T
authors.lastname: Hosobe
authors.forename: Tetsuro
authors.initials: T
authors.lastname: Kato
authors.forename: Masaki
authors.initials: M
authors.lastname: Yoshida
mesh_terms: D000328:Adult; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D002690:Chlamydia Infections / Q000188:drug therapy*; D002692:Chlamydia trachomatis; D006801:Humans; D064704:Levofloxacin; D008297:Male; D008875:Middle Aged; D009175:Mycoplasma Infections / Q000188:drug therapy*; D045704:Mycoplasma genitalium; D015242:Ofloxacin / Q000009:adverse effects / Q000627:therapeutic use*; D014526:Urethritis / Q000188:drug therapy*
chemical_list: D000900:Anti-Bacterial Agents; D064704:Levofloxacin; D015242:Ofloxacin